Last reviewed · How we verify
clarithromycin, oral, high dose
At a glance
| Generic name | clarithromycin, oral, high dose |
|---|---|
| Also known as | klacid |
| Sponsor | Andres J. M. Ferreri |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Salvage Therapy With High Dose Oral Clarithromycin in Relapsed or Refractory Extranodal Marginal Zone Lymphoma (PHASE2)
- Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease (PHASE2)
- Daily Four Times or Two Times Usage of PPI and Amoxicillin for the First or Second Line H. Pylori Eradication (NA)
- Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA) (NA)
- High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- clarithromycin, oral, high dose CI brief — competitive landscape report
- clarithromycin, oral, high dose updates RSS · CI watch RSS
- Andres J. M. Ferreri portfolio CI